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What is the key question? 
Are immunomarkers useful for predicting prognosis in fibrotic interstitial lung 
diseases? 
What is the bottom line? 
High levels of v6 integrin immunostain on VATS biopsy predict worse survival 
than low levels of immunostain.  
Why read on? 
This paper describes the first immunomarker to be associated with survival in 
fibrotic interstitial lung diseases and describes a strategy that could alter 
management of these diseases. 
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αvβ6 integrin may be a potential prognostic biomarker in Interstitial 
Lung Disease 
ABSTRACT  
Background 
Idiopathic Pulmonary Fibrosis (IPF) and fibrotic Non-Specific Interstitial 
Pneumonitis (NSIP) are progressive Interstitial Lung Diseases (ILDs) with limited 
treatment options and poor survival. However, the rate of disease progression is 
variable, implying there may be different endotypes of disease. We hypothesised 
immunophenotyping biopsies from ILD patients might reveal distinct endotypes 
of progressive fibrotic disease, that may facilitate stratification when undertaking 
clinical trials for novel therapies for IPF. 
Methods 
43 paraffin-embedded, formalin fixed lung tissue sections were immunostained 
for five molecules implicated in the pathogenesis of the fibrosis: alpha smooth 
muscle actin (SMA); v6 integrin; pro-surfactant protein c (pro-SpC); 
hepatocyte growth factor (HGF) and tenascin-c (TenC). Levels of 
immunostaining and numbers of fibroblastic foci were quantified using operator 
dependent and independent methods.  The relationship of all these markers to 
overall survival was analysed. 
Results 
Staining revealed high levels of SMA, v6 integrin, pro-SpC, HGF and Ten C, 
and fibroblastic foci. Immunostaining varied across samples for all molecules, 
but only the extent of v6 integrin immunostaining was associated with 
increased mortality. There was no association with the other markers measured.   
Conclusion  
Our data suggest high levels of v6 integrin may identify a specific endotype of 
progressive fibrotic lung disease.  
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INTRODUCTION 
Fibrotic Interstitial Lung Diseases, including Idiopathic pulmonary fibrosis (IPF) 
and fibrotic Non-Specific Interstitial Pneumonitis (NSIP) are chronic, progressive, 
diseases associated with serious morbidity and premature death. The median 
survival for IPF is approximately 3 years [1]. Currently 4500 new cases of IPF 
arise each year in the UK, and both the incidence and mortality have been rising 
for the last few decades [2]. NSIP is considered a distinct clinical entity, with a 
better prognosis compared with IPF, although many patients suffer from 
progressive disease [3]. Furthermore, there is a large group of patients with 
unclassifiable ILD with a similar progressive, but heterogenous, clinical course 
[4]. The heterogenous nature of progressive fibrotic interstitial lung diseases 
suggests there may be endotypes of disease both distinct, and common, across 
the different clinical phenotypes.  
There is considerable interest in defining endotypes of progressive fibrotic 
interstitial lung disease to both understand disease progression and to facilitate 
stratified treatment design. Transcriptional profiling is able to distinguish 
patients with stable disease from those who have progressive disease [5] and 
acute exacerbations [6], although no difference in mortality was documented. 
Studies of biopsies from patients with IPF have assessed whether the fibroblastic 
foci correlate with reduced survival but the results have not been conclusive [7 
8], and molecular phenotyping for TGFβ signalling molecules did not show any 
relationship to survival [9]. Serum and plasma biomarkers such as KL-6 [10], 
CXCL13 [11] CCL18 [12], MMP3 [13] and MMP-7 [14], have been shown to have 
prognostic value in IPF although how they reflect underlying disease 
pathogenesis, or whether they change in response to therapy, remains 
uncertain. Recently it has been hypothesised that there may be two distinct 
endotypes of disease, related to disrupted bronchiolisation and lymphoid 
aggregates, which may prove useful in developing interventional clinical trials 
[13]. 
IPF is thought to result from initial injury of alveolar epithelium leading to 
activation of lung fibroblasts, which subsequently synthesise excess matrix. The 
v6 integrin is an epithelial restricted molecule that has been implicated in 
numerous models of lung fibrosis [15-18], in patients with IPF [16 18], and 
targeted therapy is currently undergoing phase 2 evaluation in the USA 
(clinicaltrials.gov NCT01371305). Surfactant Protein C (SPC) is another epithelial 
specific protein that has been associated with IPF. SPC levels are increased in 
IPF bronchoalveolar lavage, [19], and genetic studies have implicated SPC gene 
mutations in both sporadic and familial IPF [20]. The emergence of a 
myofibroblast phenotype, characterised by SMA expression, is a key event in 
the pathogenesis of fibrosis and may be responsible for the increased 
contractility in tissues undergoing fibrosis [21]. HGF is increased in response to 
tissue injury, and inverse correlations have been identified for HGF expression 
during the development and progression of fibrosis in several tissues including 
the lung [22]. Furthermore, lung fibroblasts isolated from IPF patients have 
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decreased HGF expression and activation relative to fibroblasts from control 
patients [23]. Tenascin C is increased in fibrosis, especially in Usual Interstitial 
Pneumonitis (UIP), a hallmark of IPF [24]. It is abundant in the fibroblast foci of 
active fibrosis and is also present in the basement membrane regions beneath 
the metaplastic epithelium lining honeycomb cysts [25].  
We evaluated these molecules by immunohistochemical analysis of fibrotic ILD 
tissue, as well as quantifying fibroblastic foci, to determine whether specific 
epithelial, or mesenchymal, endotypes of progressive fibrotic lung disease exist 
to facilitate clinical trial stratification.  
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METHODS 
Reagents 
Xylene (X-0200-17) and 100% ethanol were purchased from Fisher UK. 
Hydrogen peroxide (30% H2O2), Methanol (95294-1L), 10mM Sodium citrate 
buffer, Horse serum (H0146-10ML), Goat serum (G-9023), Trizma® base, 
SIGMAFAST™ 3,3’-Diaminobenzidine tablets, Mayer’s Haematoxylin and Eosin 
(MHS32) were purchased from Sigma-aldrich, Dorset, UK. Commercially 
available ABC kit was used from Vectastain Universal ABC Kit. The antibodies 
used were anti-SMA mouse monoclonal (ab7817, clone 1A4, Abcam), Tenascin 
C mouse monoclonal (NCL-TENAS C, Novocastra), anti-c-met mouse monoclonal 
(Invitrogen, cat no 37-0100) and anti-pro surfactant protein c rabbit polyclonal 
(Millipore NG1850802) were used. The anti-v6 integrin antibody (6.2A1, 
Biogen Idec) was generated as previously described [26]. The secondary 
antibodies used were biotinylated horse anti-mouse, biotinylated goat anti-
mouse and biotinylated goat anti-rabbit (Vector Laboratories, Peterborough, 
UK).  
Patient samples 
Forty-three ILD lung sections were obtained via Video-Assisted Thoracoscopic 
Surgery (VATS) biopsy, which were formalin fixed and paraffin-embedded. The 
sections were obtained from W Wallace (University of Edinburgh). These patients 
were seen in outpatient clinic in Edinburgh from the period 1999-2009 and 
required biopsy for diagnostic purposes. All patients had a diagnosis of IPF or 
NSIP as per the international consensus criteria [27]. They were subsequently 
followed over a 10-year period to allow analysis of “all cause” mortality; 
unfortunately there are insufficient clinical data to determine the cause of death.  
The tissue samples were obtained after informed consent and local ethics 
approval (Code-South East Scotland SAHSC Bioresource 06/S1101/41). 
Immunohistochemistry 
Parallel lung tissue sections were cut and deparaffinised in xylene followed by 
rehydration in decreasing concentrations of ethanol and washed in Tris-buffered 
saline. Antigen retrieval, primary and secondary antibody for each marker has 
been listed in Supplementary Table 1 (appendix, web only file). The endogenous 
peroxidase activity was blocked using 3% H2O2 in methanol for 30 mins. The 
sections were washed twice with Tris-buffered saline and incubated with a buffer 
block of 5% goat or horse serum, for 20 min at room temperature (RT). Sections 
were incubated with primary antibody for 1 hour at RT, or overnight at 4oC. 
Subsequently, sections were washed with Tris-buffered saline and incubated for 
one hour with biotin-conjugated secondary antibody. Signal amplification was 
performed using the Vectastain standard ABC kit prior to visualisation with DAB 
for 10 min. Slides were counter stained in Mayer’s hematoxylin (Raymond A 
Lamb Limited, East Sussex, UK). Secondary antibody only controls were used for 
all experiments. 
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Quantification Analysis  
Each patients’ sample was analysed for two epithelial markers (v6 integrin and 
SpC) and three mesenchymal markers (SMA, HGF and tenascin C), therefore 
43 samples were analysed for five immunomarkers. The interpretation of 
histological sections is an inherently subjective process based primarily on 
morphologic features. When used by an experienced operator, the scoring 
methods have been shown to have statistically significant correlation with clinical 
outcomes [28]. Automated analysis has been increasingly used in recent years 
to attempt to standardize quantification. In the absence of a clear consensus on 
the most accurate quantification method, two techniques incorporating both 
semi-quantitative and automated analysis were used. 
Operator dependent, semi-quantitative analysis 
Individual patient slides contained between one and five lung sections. Five high 
power fields (HPF) per tissue section (maximum of 25 per slide) were analysed. 
To normalise for varying numbers of regions of interest per slide the mean score 
per slide was calculated. For epithelial markers the degree of staining is 
expressed as the percentage of the epithelial surface in selected HPF. For the 
purpose of quantification it was assumed that all cells on the luminal surface 
were epithelial in origin. For the mesenchymal markers, the whole section was 
taken into account for analysis and the degree of staining is expressed as a 
percentage of the whole section. To avoid overlapping analysis of individual 
tissue sections, the slides were viewed in a structured manner from right to left, 
both when analysing each tissue section and each slide. The coding was done 
prior to analysis and is as follows: 
0=Negative 
1=0-≤30% 
2=30-≤50% 
3=50-≤70% 
4=≥70% 
 
Each slide was analysed by two independent investigators blinded to the 
outcome of the patient. Weighted Kappa analysis was done to measure 
agreement between two operators. In patients where there was a disagreement, 
an average of the two was done for analysis. 
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Automated image analysis 
Automated image analysis using Nikon 90i microscope image analysis software 
(NIS Elements) was performed. A threshold using the RGB mode was selected to 
determine the pixels to be included in the section. The threshold limit was 
defined using reference points from within the image in positive control. For 
epithelial surfaces, a single point tool was used to define threshold, whilst a 3- 
point circle was used for the mesenchymal markers. Using the Threshold ND 
image tool, the thresholding was uniform for all frames. An algorithm to define a 
histological region of interest (ROI), to define signal localisation was used. The 
ROI was selected at random and was fixed in terms of area. Five HPF per section 
(up to maximum of 25 per slide) were taken for the purpose of analysis. The 
amount of stain is represented as percentage of the ROI area, with average of 
the five HPF as numerator and ROI area as denominator. 
 Fibroblastic Foci quantification 
Fibroblastic foci quantification was performed as previously described [8]. The 
following criteria were used to identify fibroblastic foci based on previously 
published definitions [8 29]: 
 Discrete sub-epithelial areas of spindle shaped myofibroblasts and 
fibroblasts 
 Linear arrangement of cells parallel to luminal surface 
 Pale staining matrix in contrast with darker parenchyma 
Five fields, using x10 objective, per tissue section (maximum of 25 per slide) 
were analysed. Each slide was analysed by two independent observers and mean 
score of the two was used for analysis. 
 
Statistics 
The start date was the date of the biopsy. The end date was taken as the date of 
death or the last known date the patient was alive (15/11/2011). Patients were 
censored on the last known date that they were alive (15/11/2011). There is no 
gold standard for IHC analyses hence the groups were divided into quartiles for 
operator dependant and tertiles for automated analysis. Ranked analysis has 
been done and p-value for trend has been shown. Cox’s Proportional Hazards 
Regression and Kaplan-Meier for survival analysis were carried out. The 
quantification was done blinded to the survival data. Spearman correlation was 
done between operator dependent and automated analysis. StataCorp. 
2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP 
was used. 
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RESULTS 
Patient demographics 
Basic demographic data are shown in Table 1. The median age of patients was 
63 years with a slight predominance of males. 36 patients had UIP and five had 
NSIP.  
Table 1: Demographics of 43 ILD patients undergoing VATS biopsy at 
Edinburgh, UK (1999-2009).   
Age (median)  63 years (43-76years) 
Sex (M:F)  24:19 (56% vs 44%) 
Diagnosis (UIP:NSIP)  36:5 (#2 were unclassifiable fibrotic 
ILD) 
Median survival after biopsy (N=43) 68 month (11 months-115months) 
 
ILD patient biopsies stain positively for a range of immunomarkers 
All sections stained positively for the five immunomarkers assessed when 
compared with secondary antibody controls (See figure 1 and figure 2).        
v6 integrin and pro-SpC stained only the epithelium (figure 1a and 1b), 
consistent with their known cellular distribution. SMA stained the myofibroblast 
in the mesenchymal regions of the fibrotic lung parenchyma (figure 2a).        
HGF was expressed diffusely in the interstitium, excluding the epithelial surfaces 
(figure 2c). Tenascin C showed positive staining in the fibrotic interstitium and 
stromal fibres underlying the immune-negative epithelium (figure 2b).  
Relationship between immunostaining and prognosis 
Weighted kappa agreement between the two investigators recording semi-
quantitative analysis was 81%. Furthermore, the semi-quantitative and 
automated analysis was strongly associated (Rs 0.83, p<0.0001). Of the five 
immunomarkers assessed only v6 integrin was found to be associated with 
prognosis, with high levels of immunostain being associated with a worse 
prognosis using both operator dependent and automated image analysis 
methodology (see table 2a & 2b). There was a four-fold increased risk of death 
(95%CI 0.87-20.23) in patients expressing highest levels of v6 integrin using 
the operator dependant analysis (p-trend: 0.0019), and two times increased risk 
of death (95%CI 0.75-5.7) in high expressers of v6 integrin using the 
automated analysis (table 2a). A worse median survival of 25months was seen 
in patients with highest expression of v6 integrin (see figure 2; log rank 
equality test, p<0.0001). Differences in survival are shown in the Kaplan-Meier 
curves (figure 3). 
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A similar trend was also seen with SMA using the operator dependant analysis 
with high levels of immunostain being associated with shorter survival, however 
these results did not reach statistical significance by either methodology (Table 
2a). 
There was no association between levels of immunostain of HGF, Ten C and pro-
SpC and prognosis by either methodology (see Table 2b). The automated image 
analysis for pro-SpC, using the RGB thresholding was giving a false high 
positivity thus only operator dependant results are shown. There was no 
difference in the results on excluding the unclassifiable biopsies.  
Relationship between fibroblastic foci and prognosis 
H&E staining was used to identify fibroblastic foci (Figure 4a). Weighted kappa 
agreement between the two investigators recording fibroblastic foci was 68%. 
Using the Cox proportional model, there was a 33% increased risk of death with 
increasing number of fibroblastic foci (HR 1.33, 95%CI 0.72-2.46), however this 
was not statistically significant (Figure 4b).  
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Table 2a: Adjusted Hazard’s ratio and 95% confidence interval (CI) for 
relationship between quantitative immunostaining and death in 43 ILD patients, 
1999-2009.  
Biomarker Method Group 
(n=number of 
patients) 
Hazard 
ratio 
95% CI  p value 
for trend 
 
vβ6 
 
Semi-
quantitative 
0-30%(n=3)      1   
0.0019 30-≤50% 
(n=14) 
   0.71 0.134-
3.80 
50-≤70% 
(n=12) 
   0.76 0.15-3.88 
 >70% (n=14)    4.19 0.87-
20.23 
Automated Group 1(n=15) 
Low expression 
   1  0.25 
Group 2(n=14) 
Medium 
expression 
0.98 0.32- 3.06 
Group 3(n=14) 
High 
expression 
2.07 0.75-5.7 
 
SMA 
 
Semi-
quantitative 
0-30% (n=2)    1   
0.49 30-≤50%(n=8)   0.99 0.10-9.74 
50-≤70% 
(n=12) 
  4.54 0.49-
41.93 
 >70% (n=21)   1.77 0.22-
14.01 
Automated Group 1(n=15) 
Low expression 
  1  0.72 
Group 2(n=14) 
Medium 
expression 
1.23 0.41-3.73 
Group 3(n=14) 
High 
expression 
1.54 0.52-4.54 
Adjusted for age and sex 
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Table 2b: Adjusted Hazard’s ratio and 95% confidence interval (CI) for 
relationship between quantitative immunostaining and death in 43 ILD patients, 
1999-2009.  
Biomarker Method Group 
(n=number of 
patients) 
Hazard 
ratio 
95% CI  p value 
for trend 
HGF Semi-
quantitative 
0-30%(n=1)   1  0.94 
30-
<50%(n=12) 
  0.63 0.074-
5.30 
50-
<70%(n=13) 
  0.60 0.070-
5.09 
 >70%(n=17)   0.71 0.087-
5.75 
Automated Group 1(n=15) 
Low expression 
  1  0.41 
Group 2(n=14) 
Medium 
expression 
1.70 0.65-4.48 
Group 3(n=14) 
High 
expression 
0.84 0.28-2.52 
 
SPC¶ 
 
Semi-
quantitative 
0-30%(n=12)   1   
0.99 30-
≤50%(n=14) 
  1.17 0.37-3.70 
50-≤70%(n=9)   1.25 0.32-4.78 
 >70%(n=8)   1 0.30-3.28 
 
Tenascin-
C§ 
Semi-
quantitative 
    1.16 0.36-1.97 0.58 
Automated Group 1(n=15) 
Low expression 
  1  0.57 
Group 2(n=14) 
Medium 
expression 
1.62 0.55-4.83 
Group 3(n=14) 
High 
expression 
1.76 0.55-5.62 
 
¶ Automated analysis was not possible for SPC due to a high degree of false 
positive staining. 
§ Only the trend for semi-quantitative method is shown, as there were no 
deaths in Group 4. Adjusted for age and sex. 
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DISCUSSION 
These data show that high levels of v6 integrins are significantly associated 
with poor prognosis. There is also a trend towards worse prognosis with high 
levels of SMA. However, there were no differences observed between samples 
with UIP or NSIP histology, although this study was not sufficiently powered to 
detect a difference between the two groups. Furthermore, there was no apparent 
relationship between the number of fibroblastic foci and mortality consistent with 
previous reports [8]. This is the first study to demonstrate a tissue 
immunomarker in ILD with a significant association with the prognosis. A notable 
observation is the median survival of patients with the highest expression of the 
v6 integrin was only 25 months, which is comparable to the published survival 
data in IPF. This suggests that increased expression of the v6 integrin may 
represent a distinct endotype of progressive fibrotic ILD and could be useful as a 
biomarker for disease progression, and stratification of therapy. 
There have been a number of studies that have tried to characterise molecular 
endotypes in ILD [7 30-32]. The phenotype, which has been consistently shown 
to associate with poor survival on lung biopsy, is the presence of high levels of 
fibroblastic foci [7 9 32]. However, the assessment of fibroblastic foci relies on 
conventional histological techniques, and does not reflect precise molecular 
endotyping. We did not find a significant association between either high 
numbers of fibroblastic foci, or high levels of SMA, and prognosis. These data 
are consistent with previous studies which have found only weak, non 
significant, correlations of active myofibroblasts with disease severity [31]. 
However, there was a trend towards a worse prognosis with higher levels of both 
fibroblastic foci and SMA, which supports the notion that fibroblastic foci are an 
adverse feature in IPF biopsies but larger studies may be required to accurately 
quantify this effect. 
The role of v6 integrins in the pathogenesis of pulmonary fibrosis is well 
established and v6 immunostaining is increased in IPF, compared with control 
lung tissue [16-18]. Furthermore, a humanized anti-v6 monoclonal antibody, 
STX-100, is currently being evaluated in a Phase 2 study. However, the 
association of v6 integrin levels with prognosis of fibrotic ILDs has not been 
previously assessed. However, endotyping by tissue biopsy is an invasive 
procedure carrying significant mortality and morbidity irrespective of the mode 
of biopsy [33 34]. The short term mortality post lung biopsy in IPF is higher 
compared with other interstitial diseases[35]. Furthermore, there is an inherent 
sample bias in the surgical biopsies due to the patchy nature of the disease, and 
assessment of a limited number of tissue sections within the whole lung biopsy. 
This is noted irrespective of the modality of the procedure undertaken to obtain 
the surgical lung biopsies (VATS, Open lung or transbronchial lung biopsies) 
[36]. An alternative to immunohistological assessment of lung biopsies could be 
through CT/SPECT imaging. This technique is highly sensitive and able to 
globally quantify v6 integrin levels within the lung [37]. Therefore, molecular 
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imaging of the v6 integrin may have advantages over immunohistochemistry 
as a prognostic biomarker in fibrotic ILDs. 
The strength of the study is the robust quantification methodology used for the 
tissue biomarkers. This study shows that operator analysis is similar to 
automated analysis. At present, the automated analysis is an expensive modality 
and often a research tool, whereas chromogenic staining is a well-established 
technique requiring only a standard microscope. In parallel with advances in 
cancer management, recent NICE guidance in United Kingdom proposes a 
multidisciplinary team (MDT) approach to IPF, and emphasises the importance of 
the pathologist [38]. The importance of these members of the MDT will become 
even greater if molecular phenotyping of lung biopsies follow the trajectory 
observed in lung cancer. However, interobserver variation and pathologist kappa 
scores are moderate even in the most robust of studies [32 39], and the number 
of biopsies to be performed is likely to remain a small proportion of the total, 
due to the technical issues described previously. Therefore, exploring non-
invasive strategies to define prognosis and response to therapy remains crucial.  
The main limitation of the study lies in the small cohort size. Despite this the 
association of high levels of v6 integrin immunostaining with poor outcome 
was significant. Furthermore, a trend suggesting that high levels of SMA, and 
high numbers of fibroblastic foci, also lead to worse prognosis supported 
previous observations, and a larger cohort may aid confirmation. Whether a 
large prospective study defining the role of immunomarkers in IPF is a 
possibility, given the limitations of the diagnostic lung biopsy, in contrast with 
the strength of the diagnostic CT scan, remains to be seen. Another limitation of 
the study is the absence of a control population, however this study was 
designed to address the role of these molecules as prognostic, not diagnostic 
biomarkers. Conventional controls for IPF immunohistochemistry are areas of 
normal lung taken from lung cancer patients undergoing lung resection and 
clearly this would not be an appropriate control for a prognostic study and 
patients with truly normal lung do not undergo lung biopsy.  
Despite the limitations of our study, the observations described are important 
because they highlight that molecular markers have potential to aid stratification 
and the determination of prognosis in IPF. Furthermore, given the importance of 
histopathology in the management of ILDs, it is vital that as much information 
can be gained from biopsies as possible, and molecular endotyping may increase 
their utility. Ultimately this study demonstrates that high levels of the epithelial 
restricted v6 integrin may identify an endotype of progressive fibrotic ILD with 
a poor prognosis, which may be appropriate for therapeutic targeting. 
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Figure legends 
Figure 1: Immunohistochemical staining in paraffin-embedded, formalin fixed 
surgical lung biopsies in 43 fibrotic ILD patients. Immunostaining shows high 
levels of Epithelial markers: αvβ6 integrin and pro-SpC compared with secondary 
antibody only control as comparator. Representative sections of IPF lung are 
shown with control for each immunomarker. 
Immunostaining magnification= originalx20.  
a) αvβ6 integrin staining in the alveolar epithelial cells. 
b) pro-SpC immunostain in the cytoplasm of the epithelial cell layer in a patchy 
distribution. 
c) αvβ6 integrin secondary antibody control  
d) pro-SpC secondary antibody control 
 
 
Figure 2: Immunohistochemical staining in paraffin-embedded, formalin fixed 
surgical lung biopsies in 43 fibrotic ILD patients. Immunostaining shows high 
levels of Mesenchymal markers markers: αsma, HGF and Ten C, compared with 
secondary antibody only control as comparator. Representative sections of IPF 
lung are shown with control for each immunomarker. 
Immunostaining magnification= originalx20.  
a) αsma immunostain within the fibroblastic foci, showing cluster of cells 
composed of myofibroblasts. 
b) Ten C immunostain in the stromal fibres beneath the immune-negative 
epithelial layer. 
c) HGF present diffusely in the interstitium along with negatively immune-
stained alveolar epithelial cells, consistent with its known location. 
d) Secondary antibody controls for a-c. 
 
  
Figure 3: Kaplan-Meier survival for αvβ6 integrin immunomarker in 43 ILD 
patients with VATS biopsy. Survival graph of αvβ6 integrin expression, with the 
highest expressing Group 4 (bold line) vs Group 1 (dashed line), Group 2 (short 
dashed line) and Group 3 (dotted line). Median survival of Group 4 vs. Group 1-3 
was 25 months and 92 months respectively (p=0.0019). 
Figure 4: Assessment of fibroblastic foci (FF) in paraffin-embedded, formalin 
fixed surgical lung biopsies in 43 fibrotic ILD patients.  
a) Section of lung tissue illustrating FF (highlighted by arrows) using 10x 
objective. Scale bar shows 100µm. 
b) Kaplan-Meier survival of fibroblastic foci in 43 ILD patients following VATS 
biopsy. Group 1 (<1.3 FF/section), Group 2 (1.3<3 FF/section) and Group 3 
(3<7 FF/section). 
 
